Dr Michael Winlo

Emyria has completed a strongly supported placement, to support the scale-up of its MDMA-assisted therapy programs. 

In this interview, Emyria Managing Director Dr Michael Winlo explains the potential for the company’s new therapy program to treat Post-Traumatic Stress Disorder.

Elyria is advancing the MDMA molecule itself and refining its interaction with primary neurotransmitters like serotonin and dopamine.